Progress in GABAB PAM and Dipraglurant Programs
Addex Therapeutics made excellent progress in their GABAB PAM program for chronic cough and dipraglurant post-stroke recovery. Preclinical characterization and IND-enabling studies have been successfully completed.
Strategic Collaborations and Investments
Addex's partner, Indivior, completed IND-enabling studies for a substance use disorders drug candidate. Addex also invested in Stalicla, which is advancing patient stratification studies in autism and discussions with pharma for broader applications.
Strong Cash Position
The company ended Q3 2025 with CHF 2.2 million in cash, providing a runway through mid-2026. The cash burn has been significantly reduced following the Neurosterix spinout transaction.